ATE334199T1 - Modifizierte faktor viii cdna - Google Patents

Modifizierte faktor viii cdna

Info

Publication number
ATE334199T1
ATE334199T1 AT00104677T AT00104677T ATE334199T1 AT E334199 T1 ATE334199 T1 AT E334199T1 AT 00104677 T AT00104677 T AT 00104677T AT 00104677 T AT00104677 T AT 00104677T AT E334199 T1 ATE334199 T1 AT E334199T1
Authority
AT
Austria
Prior art keywords
factor viii
viii cdna
modified factor
cdna
modified
Prior art date
Application number
AT00104677T
Other languages
English (en)
Inventor
Claude Dr Negrier
Jean Luc Plantier
Original Assignee
Negrier Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Negrier Claude filed Critical Negrier Claude
Application granted granted Critical
Publication of ATE334199T1 publication Critical patent/ATE334199T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00104677T 1999-03-17 2000-03-03 Modifizierte faktor viii cdna ATE334199T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99104050A EP1038959A1 (de) 1999-03-17 1999-03-17 Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält

Publications (1)

Publication Number Publication Date
ATE334199T1 true ATE334199T1 (de) 2006-08-15

Family

ID=8237678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00104677T ATE334199T1 (de) 1999-03-17 2000-03-03 Modifizierte faktor viii cdna

Country Status (9)

Country Link
US (2) US6271025B1 (de)
EP (1) EP1038959A1 (de)
JP (1) JP2000287694A (de)
KR (1) KR100705996B1 (de)
AT (1) ATE334199T1 (de)
AU (1) AU769826B2 (de)
CA (1) CA2300782A1 (de)
DE (1) DE60029509T2 (de)
ES (1) ES2269033T3 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
EP1048726B1 (de) * 1999-04-27 2006-07-26 Négrier, Claude Modifizierte Faktor VIII cDNA
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
EP1231220B1 (de) * 2001-02-09 2009-05-13 Claude Négrier Modifizierte Faktor VIII cDNA und ihre Verwendung zur Produktion von Faktor VIII
EP1284290A1 (de) * 2001-08-08 2003-02-19 Aventis Behring GmbH Erhöhung der Expression von Faktor VIII durch Insertion von spleissbaren Nukleotidsequenzen in Faktor VIII cDNA
WO2003057709A2 (en) * 2001-10-19 2003-07-17 Sirna Therapeutics, Inc Method and reagent for the detection of proteins and peptides
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
DE602004018349D1 (de) * 2003-10-16 2009-01-22 Claude Negrier MODIFIZIERTE cDNA FÜR HOHE EXPRESSIONSNIVEAUS VON FAKTOR VIII UND DESSEN DERIVATEN
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
LT3013855T (lt) 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
MX2018012537A (es) 2016-04-15 2019-02-25 Univ Pennsylvania Terapia de genes para tratar hemofilia a.
GB201614462D0 (en) * 2016-08-24 2016-10-05 Univ Sheffield Clotting factor
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
WO2022211791A1 (en) 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
ATE335083T1 (de) 1993-02-26 2006-08-15 Novozymes As Methode und system zur erhöhten produktion von kommerziell wichtigen exoproteinen in gram- positiven bakterien
FR2763959A1 (fr) 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
EP1048726B1 (de) 1999-04-27 2006-07-26 Négrier, Claude Modifizierte Faktor VIII cDNA
EP1231220B1 (de) 2001-02-09 2009-05-13 Claude Négrier Modifizierte Faktor VIII cDNA und ihre Verwendung zur Produktion von Faktor VIII

Also Published As

Publication number Publication date
AU2231200A (en) 2000-11-09
KR20000076862A (ko) 2000-12-26
AU769826B2 (en) 2004-02-05
US20020165177A1 (en) 2002-11-07
US6800461B2 (en) 2004-10-05
EP1038959A1 (de) 2000-09-27
DE60029509D1 (de) 2006-09-07
JP2000287694A (ja) 2000-10-17
US6271025B1 (en) 2001-08-07
ES2269033T3 (es) 2007-04-01
DE60029509T2 (de) 2007-03-08
KR100705996B1 (ko) 2007-04-13
CA2300782A1 (en) 2000-09-17

Similar Documents

Publication Publication Date Title
ATE334199T1 (de) Modifizierte faktor viii cdna
USD438617S1 (en) Portion of an adaptor for a medical instrument
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
DE60017336D1 (de) Zusammensetzung zur Herstellung von Harzen
MY103352A (en) Piperazinyl-heterocyclic compounds
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
DE60029566D1 (de) In-vitro herstellung von transplantierbarem knorpelgewebe
GR3035526T3 (en) Retroviral protease inhibitors.
DE60020943D1 (de) HYDANTOINASE-VARIANTEN MIT VERBESSERTEN EIGENSCHAFTEN UND IHRE ANWENDUNG ZUR PRODUKTION VON AMINOSäUREN
ATE526300T1 (de) Octenzusammensetzung
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
SE9201628D0 (sv) Pharmaceutical composition
PT1490492E (pt) Gene do factor de crescimento de hepatócitos híbrido com eficiência de expressão elevada de dois heterotipos do factor de crescimento de hepatócitos
EP1048726A3 (de) Modifizierte Faktor VIII cDNA
DE60232282D1 (de) Modifizierte Faktor VIII cDNA und ihre Verwendung zur Produktion von Faktor VIII
IL87421A (en) Pharmaceutical compositions containing 5-amino (or substituted amino) - 1,2,3-triazoles
IL126235A0 (en) Compounds with growth hormone releasing properties
AU2003285346A1 (en) Regulatory elements in the 5' region of the vr1 gene
WO2000023587A3 (en) Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
GB9302046D0 (en) Antiumoral compound-v
IT9019101A0 (it) Procedimento per la stabilizzazione particolarmente di mosto d'uva
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
HUP9901751A3 (en) Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
DE69706562D1 (de) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamidhydrat
IL137007A0 (en) Compounds with growth hormone releasing properties

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1048726

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties